{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Long Y"],"funding":["Chongqing Medical University"],"pagination":["152-158"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8289697"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["571"],"pubmed_abstract":["Potent neutralizing antibodies (Abs) have been proven with therapeutic efficacy for the intervention against SARS-CoV-2. Majority of these Abs function by directly interfering with the virus entry to host cells. Here, we identified a receptor binding domain (RBD) specific monoclonal Ab (mAb) 82A6 with efficient neutralizing potency against authentic SARS-CoV-2 virus. As most Abs targeting the non-receptor binding motif (RBM) region, 82A6 was incapable to block the RBD-ACE2 interaction. In particular, it actively promoted the S1 subunit shedding from the S protein, which may lead to effective reduction of intact SARS-CoV-2 viruses. Importantly, it could block potential syncytia formation associated with post-infectious cell surface expression of S proteins. Our study evidenced a RBD specific Ab with unique beneficial efficacy against SARS-CoV-2 infection, which might bring informative significance to understand the collective effects of neutralizing Abs elicited in COVID-19 patients."],"journal":["Biochemical and biophysical research communications"],"pubmed_title":["A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding."],"pmcid":["PMC8289697"],"funding_grant_id":["X4457"],"pubmed_authors":["Hu C","Li S","Jin A","Long Y","Li T","Zhang H","Song S","Luo F","Han X","Wang W","Wang Y","Zhang B"],"additional_accession":[]},"is_claimable":false,"name":"A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding.","description":"Potent neutralizing antibodies (Abs) have been proven with therapeutic efficacy for the intervention against SARS-CoV-2. Majority of these Abs function by directly interfering with the virus entry to host cells. Here, we identified a receptor binding domain (RBD) specific monoclonal Ab (mAb) 82A6 with efficient neutralizing potency against authentic SARS-CoV-2 virus. As most Abs targeting the non-receptor binding motif (RBM) region, 82A6 was incapable to block the RBD-ACE2 interaction. In particular, it actively promoted the S1 subunit shedding from the S protein, which may lead to effective reduction of intact SARS-CoV-2 viruses. Importantly, it could block potential syncytia formation associated with post-infectious cell surface expression of S proteins. Our study evidenced a RBD specific Ab with unique beneficial efficacy against SARS-CoV-2 infection, which might bring informative significance to understand the collective effects of neutralizing Abs elicited in COVID-19 patients.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-26T00:30:34.785Z","creation":"2025-04-06T09:40:45.931Z"},"accession":"S-EPMC8289697","cross_references":{"pubmed":["34325131"],"doi":["10.1016/j.bbrc.2021.07.062"]}}